Article: InterMune Provides Update on Its Two Phase III Pulmonology Programs.

- Phase III INSPIRE Trial on Track to Conclude Around the End of 2007 -

- Design of Phase III Pirfenidone Program Finalized -

- Company to Host Conference Call Tomorrow Morning at 8:30 A.M. ET -

BRISBANE, Calif., October 17 /PRNewswire-FirstCall/ -- InterMune, Inc. today provided an update on its two Phase III programs evaluating two separate compounds for the treatment of idiopathic pulmonary fibrosis (IPF). The update included the status of enrollment of the Phase III INSPIRE trial for Actimmune(R) (interferon gamma-1b) and details regarding the finalized protocol design of the Phase III pirfenidone program.

Strong INSPIRE Trial ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!